Clinical Scorecard: Efficacy and Safety of Bimekizumab in Psoriatic Arthritis Patients with Significant Skin and Nail Involvement Over One Year

At a Glance

Key Highlights

• Bimekizumab demonstrated clinically meaningful improvements versus placebo at week 16 across PsA disease domains including skin and nails.
• Efficacy was consistent and sustained through week 52 in both biologic-naïve and TNFi-IR participants.
• Bimekizumab was well tolerated with no new safety signals identified over one year.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of PsA should meet CASPAR criteria with active joint, skin, and nail involvement.
• Assessment should include tender and swollen joint counts, plaque psoriasis extent (≥3% BSA), and nail psoriasis severity (mNAPSI).

Management

• Bimekizumab 160 mg subcutaneously every 4 weeks is effective for PsA patients with significant skin and nail disease.
• Treatment goals include achieving minimal disease activity across all core domains to improve quality of life.
• Consider bimekizumab for biologic-naïve patients or those with inadequate response/intolerance to TNF inhibitors.

Monitoring & Follow-up

• Monitor clinical response across joint, skin, and nail domains regularly, including mNAPSI and psoriasis BSA.
• Assess for adverse events and tolerability throughout treatment duration.
• Evaluate health-related quality of life and disease impact periodically.

Risks

• No new safety signals were identified with bimekizumab over one year.
• Standard monitoring for immunomodulatory therapy adverse effects is recommended.

Patient & Prescribing Data

Adults with active PsA and concomitant moderate-to-severe plaque psoriasis and nail involvement, biologic-naïve or TNFi-IR

Bimekizumab provides sustained improvements in joint, skin, and nail symptoms with a favorable safety profile over 52 weeks.

Clinical Best Practices

• Use validated criteria (CASPAR) and scoring tools (mNAPSI, BSA) to assess disease severity and treatment response.
• Target treatment to achieve minimal disease activity across all PsA domains to maximize quality of life.
• Consider bimekizumab as a treatment option for patients with significant skin and nail involvement, including those with prior TNFi failure.
• Monitor patients regularly for efficacy and safety, adjusting therapy as needed.

References

• Digital Features and Graphical Abstract
• BE OPTIMAL Study (NCT03895203)
• BE COMPLETE Study (NCT03896581)
• BE VITAL Study (NCT04009499)
• Global Regulatory Approvals for Bimekizumab